



## Proteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017

September 5, 2017

WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- [Proteon Therapeutics Inc.](#) (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the Baird 2017 Global Healthcare Conference on September 7, 2017 at 9:40 a.m. ET in New York, NY.

### About Proteon Therapeutics

Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug intended to improve hemodialysis vascular access outcomes. Proteon is currently enrolling patients in PATENCY-2, a Phase 3 clinical trial evaluating vonapanitase in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial in patients with peripheral artery disease (PAD). For more information, please visit [www.proteontx.com](http://www.proteontx.com).

### Investor Contact

George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer  
781-890-0102  
[geldridge@proteontherapeutics.com](mailto:geldridge@proteontherapeutics.com)

### Media Contact

Ann Stanesa, Ten Bridge Communications  
617-230-0347  
[proteon@tenbridgecommunications.com](mailto:proteon@tenbridgecommunications.com)

### Primary Logo

Proteon Therapeutics, Inc.